Girolamo Calò Selected Research

Nociceptin

1/2021	Functional Selectivity Does Not Predict Antinociceptive/Locomotor Impairing Potencies of NOP Receptor Agonists.
1/2021	Novel Mixed NOP/Opioid Receptor Peptide Agonists.
3/2018	Involvement of the N/OFQ-NOP system in rat morphine antinociceptive tolerance: Are astrocytes the crossroad?
1/2017	Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction.
5/2016	Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.
4/2016	Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma.
11/2015	Intrathecal administration of nociceptin/orphanin FQ receptor agonists in rats: A strategy to relieve chemotherapy-induced neuropathic hypersensitivity.
5/2013	Nociceptin/orphanin FQ receptor activation decreases the airway hyperresponsiveness induced by allergen in sensitized mice.
3/2005	Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux.
8/2003	Nociceptin/orphanin FQ and its receptor--potential targets for pain therapy?

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Girolamo Calò Research Topics

Disease

8	Pain (Aches) 01/2021 - 08/2003
3	Substance-Related Disorders (Drug Abuse) 01/2021 - 01/2017
3	Respiratory Hypersensitivity 04/2016 - 02/2010
2	Cough 01/2021 - 03/2005
1	Opioid-Induced Constipation 07/2021
1	Constipation 08/2020
1	Body Weight (Weight, Body) 05/2018
1	Mental Disorders (Mental Disorder) 03/2017
1	Parkinson Disease (Parkinson's Disease) 05/2016
1	Asthma (Bronchial Asthma) 04/2016
1	Neurogenic Inflammation 04/2016
1	Breast Neoplasms (Breast Cancer) 11/2015
1	Hypersensitivity (Allergy) 11/2015
1	Neuralgia (Stump Neuralgia) 11/2015
1	Osteoarthritis 01/2013
1	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 11/2011
1	Hyperalgesia 01/2010
1	Anxiety Disorders (Anxiety Disorder) 12/2008
1	Gastroesophageal Reflux (GERD) 03/2005
1	Parkinsonian Disorders (Parkinsonism) 12/2004
1	Urinary Incontinence 05/2003

Drug/Important Bio-Agent (IBA)

11	NociceptinIBA 01/2021 - 05/2003
5	Morphine (MS Contin)FDA LinkGeneric 08/2020 - 01/2010
4	Opioid Analgesics (Opioids)IBA 07/2021 - 08/2003
3	Biological ProductsIBA 01/2021 - 03/2017
3	Anti-Anxiety Agents (Anxiolytics)IBA 03/2017 - 12/2008
3	Capsaicin (Zostrix)FDA Link 02/2010 - 03/2005
2	mu Opioid Receptors (mu Opioid Receptor)IBA 07/2021 - 08/2020
2	NeuropeptidesIBA 01/2021 - 05/2016
2	Opioid Receptors (Opioid Receptor)IBA 03/2018 - 11/2015
2	LigandsIBA 03/2017 - 04/2016
2	Analgesics (Analgesic Drugs)IBA 03/2017 - 08/2003
2	Nphe(1)- (pF)Phe(4)- Aib(7)- Arg(14)- Lys(15)- nociceptin-amideIBA 11/2015 - 01/2010
1	naloxegolIBA 07/2021
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2021
1	Nociceptin ReceptorIBA 01/2021
1	Antitussive Agents (Antitussives)FDA Link 01/2021
1	A-factor (Streptomyces)IBA 05/2018
1	Codeine (Codeine Phosphate)FDA LinkGeneric 05/2018
1	Nootropic Agents (Nootropics)IBA 03/2017
1	Pharmaceutical PreparationsIBA 03/2017
1	Dopamine (Intropin)FDA LinkGeneric 05/2016
1	Immunologic Factors (Immunomodulators)IBA 04/2016
1	Bronchodilator Agents (Bronchodilators)IBA 04/2016
1	Opioid Peptides (Opioid Peptide)IBA 11/2015
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2015
1	Paclitaxel (Taxol)FDA LinkGeneric 11/2015
1	AllergensIBA 05/2013
1	Hyaluronic Acid (Hyaluronan)IBA 01/2013
1	TachykininsIBA 03/2005
1	Peptide Receptors (Peptide Receptor)IBA 05/2003

Therapy/Procedure

2	Therapeutics 12/2004 - 08/2003
1	Drug Therapy (Chemotherapy) 11/2015
1	Analgesia 08/2003